Prime Medicine, Inc. Contracts & Agreements
41 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (4)
- Human Resources (15)
- Intellectual Property (10)
- Uncategorized (2)
- Securities Purchase Agreement, dated September 28, 2024, by and between Juno Therapeutics, Inc. and the Registrant (Filed With SEC on November 12, 2024)
- Research Collaboration and License Agreement, dated September 28, 2024, by and between Juno Therapeutics, Inc. and the Registrant (Filed With SEC on November 12, 2024)
- Amendment No. 4 to License Agreement, dated September 27, 2024, by and between the Broad Institute, Inc. and the Registrant (Filed With SEC on November 12, 2024)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 8, 2024)
- Description of Securities (Filed With SEC on March 1, 2024)
- Amendment No. 12 to License Agreement, dated October 2, 2023, between MIL 21E, LLC and the Registrant (Filed With SEC on March 1, 2024)
- Underwriting Agreement, dated February 14, 2024, by and between Prime Medicine, Inc. and J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and BMO Capital Markets... (Filed With SEC on February 16, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on February 16, 2024)
- Employment Agreement, effective as of January 17, 2024 (Filed With SEC on January 5, 2024)
- Amendment No. 1 to the Amended and Restated Employment Agreement, dated (Filed With SEC on November 3, 2023)
- Sixth Amendment to License Agreement, dated April 5, 2022, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- Ninth Amendment to License Agreement, dated March 17, 2023, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- Tenth Amendment to License Agreement, dated April 14, 2023, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- Eleventh Amendment to License Agreement, dated May 4, 2023, between Prime Medicine, Inc. and MIL 21E, LLC (Filed With SEC on August 7, 2023)
- 2019 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (Filed With SEC on October 13, 2022)
- 2022 Stock Option and Incentive Plan and forms of award agreements thereunder (Filed With SEC on October 13, 2022)
- 2022 Employee Stock Purchase Plan (Filed With SEC on October 13, 2022)
- Form of Executive Employment Agreement (Filed With SEC on October 13, 2022)
- Form of Underwriting Agreement (Filed With SEC on September 23, 2022)
- Amended and Restated Investors Rights Agreement among the Registrant and certain of its stockholders, dated April 20, 2021 (Filed With SEC on September 23, 2022)
- Form of Common Stock Certificate (Filed With SEC on September 23, 2022)
- 2019 Stock Option and Grant Plan, as amended, and forms of award agreements thereunder (Filed With SEC on September 23, 2022)
- Senior Executive Cash Incentive Bonus Plan (Filed With SEC on September 23, 2022)
- Non-Employee Director Compensation Policy (Filed With SEC on September 23, 2022)
- Form of Officer Indemnification Agreement (Filed With SEC on September 23, 2022)
- Form of Director Indemnification Agreement (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 7, 2022, between the Registrant and Keith Gottesdiener (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 20, 2022, between the Registrant and Jeremy Duffield (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 11, 2022, between the Registrant and Ann Lee (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 7, 2022, between the Registrant and Carman Alenson (Filed With SEC on September 23, 2022)
- Amended and Restated Employment Agreement, dated July 7, 2022, between the Registrant and Meredith Goldwasser (Filed With SEC on September 23, 2022)
- Collaboration and License Agreement, dated September 26, 2019, between Beam Therapeutics (Filed With SEC on September 23, 2022)
- License Agreement, dated September 26, 2019, between The Broad Institute, Inc. and the Registrant, as amended (Filed With SEC on September 23, 2022)
- Amendment No. 1 to License Agreement, dated May 5, 2020, between The Broad Institute, Inc. and the Registrant (Filed With SEC on September 23, 2022)
- Amendment No. 2 to License Agreement, dated February 18, 2021, between The Broad Institute, Inc. and the Registrant (Filed With SEC on September 23, 2022)
- Pledge from Prime Medicine (Filed With SEC on September 23, 2022)
- License Agreement, dated March 16, 2020, between MIL 21E, LLC and the Registrant, as amended (Filed With SEC on September 23, 2022)
- Consulting Agreement between the Registrant and David Liu, dated September 13, 2019 (Filed With SEC on September 23, 2022)
- Amendment No. 1 to the Consulting Agreement between the Registrant and David Liu, dated October 22, 2021 (Filed With SEC on September 23, 2022)
- Andrew Anzalone Offer Letter, dated December 20, 2019 (Filed With SEC on September 23, 2022)
- Andrew Anzalone Confidentiality, Assignment and Nonsolicitation Agreement, dated October 16, 2020 (Filed With SEC on September 23, 2022)
